Biotech and genomics companies Longenesis and Dante Genomics launch more personalised genomic services to more than 10,000 people across the Baltics and Italy, thus expanding and bridging the reach of valuable health insight delivery to patients across Europe.
1 November, 2022, RIGA, LATVIA — Latvian Biotechnology startup Longenesis has partnered with Dante Genomics, a global company of genomics and precision medicine, to offer whole genome sequencing (WGS) to more than 10,000 existing Longenesis study participants.
WGS and Dante’s subsequent genomic reports are valuable health tools that can provide physicians and individuals with information about personalised dietary choices, predisposition to genetic diseases, genetic carrier information and more. Traditionally, DNA tests have been limited in the Baltic and Mediterranean regions due to cost and availability of practitioners, services and resources. Longenesis will enrich its digital educational engagement platform skrinings.lv by providing its network of participants discounted Dante offerings, including at-home, blood collection kits for WGS without the use of a needle and additional women’s health reports without the need to re-test. This collaboration will encourage more people to pursue genomic solutions to help make personalized medicine more mainstream across Europe.
The Longenesis platform offers a digital, dynamic, secure engagement tool that empowers the public to explore and start using Dante’s novel genomic solutions. The digital tools will ensure legal and ethical compliances built into the Longenesis platform and offer streamlined consent for nearly 20,000 people globally.
“Our new partnership with Dante Genomics will make it easier for women to access exciting new DNA testing opportunities that will provide greater health insights. Everyone deserves to have individualised understanding of their health DNA testing affords. We are excited to work with Dante Genomics to expand our European reach and positively impact more people’s lives,” said Paolo Malerba, the VP of Partnerships and Strategy at Longenesis.
“Personalized medicine needs personalized data, and it is through collaborations like these that will allow us to offer more people in more regions of the world with genomic solutions,” said Andrea Riposati, CEO of Dante Genomics. “We are excited to partner with Longenesis to increase access to these invaluable genomic solutions that can improve women’s health and ultimately save lives.”
Skrinings.lv is an online health platform that empowers individuals to learn more about their health. Developed by specialists from the medical, technology, and design fields, the platform aims to establish a culture of preventative healthcare in Latvia as well as educate women on breast cancer risks and contraception methods. By educating more individuals and collecting real-world data, skrinings.lv is actively contributing to decreasing unwanted pregnancies, lowering the spread of sexually transmitted diseases and helping women take control of their reproductive health. Learn more at www.skrinings.lv/en.
Take the breast cancer risk assessment test at https://skrinings.lv/en/breast-health.
Longenesis is a SaaS company that is unlocking a healthier future for humans. Supported by Insilico Medicine and other technology leaders, Longenesis has built an end-to-end, intuitive toolkit for data discovery and patient-centric engagement in medical studies. Our flagship products, Curator and Engage, are highly secure and designed for patients to remain in control of their personal data while also empowering them to share their information with doctors and researchers worldwide. Through these products, we unlock the hidden value of data, accelerate novel drug and treatment discovery and ensure better and proactive patient engagement. Our mission is to help modernise the approach to human health. At Longenesis, we firmly believe the future medical system will be collaborative. We build a technological bridge between healthcare institutions, pharma companies, research institutions and patients. We are proud to partner with leading educational and research institutions, global life sciences companies, healthcare stakeholders, and patient advocacy groups in service of this mission. Learn more at www.longenesis.com.
About Dante Genomics
Dante Genomics is a global genomic data company building and commercialising a new class of transformative health and longevity applications based on whole genome sequencing and AI. Their assets include one of the largest private genome databases with research consent, a proprietary software platform designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.